Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) is a clinical-stage biopharmaceutical company dedicated to developing innovative oncology therapies targeting cancers with significant unmet medical needs. The company's diverse product pipeline aims to address a wide range of malignancies, advancing novel therapeutic approaches with the potential to significantly improve patient outcomes.
One of Oncternal's flagship products is zilovertamab, a humanized monoclonal antibody that targets the receptor-tyrosine kinase-like orphan receptor 1 (ROR1). Currently in Phase 1/2 clinical trial, zilovertamab is being tested in combination with ibrutinib for mantle cell lymphoma and chronic lymphocytic leukemia, as well as in combination with paclitaxel for HER2-negative metastatic breast cancer.
Another key product in the pipeline is ONCT-216, a small molecule designed to inhibit ETS-family oncoproteins. ONCT-216 is undergoing Phase 1 trials to treat Ewing sarcoma, among other potential indications.
Oncternal is also developing ONCT-808, a CAR-T cell therapy targeting ROR1, showing promise in preclinical models against various hematological malignancies and solid tumors. Furthermore, ONCT-534, a dual-action androgen receptor inhibitor, is in Phase 1/2 trials for advanced prostate cancer, addressing resistance mechanisms common in patients who have relapsed after standard treatments.
Financially, Oncternal remains robust, with ongoing clinical trials supported by solid operational funding. The company maintains strategic partnerships and collaborations to foster innovation and expedite the development of its therapeutic candidates. With a focus on unmet medical needs, Oncternal Therapeutics is at the forefront of oncology research, aiming to bring new hope to patients worldwide.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced on February 1, 2023, the granting of an inducement award to Jennifer Neumann, who joined as Director of Clinical Data Management. The award includes an option to purchase 33,300 shares of ONCT common stock at the closing price on the grant date, with a 10-year term and a four-year vesting schedule. This was conducted under the company's 2021 Employment Inducement Incentive Award Plan, approved by the independent compensation committee, aligning with Nasdaq regulations. Oncternal focuses on developing oncology therapies for unmet medical needs, particularly in hematological malignancies and prostate cancer.
Oncternal Therapeutics (Nasdaq: ONCT) appointed Jill DeSimone to its board of directors, bringing extensive experience in oncology. DeSimone previously led Merck's U.S. Oncology division, growing it to over $9 billion. This appointment aligns with Oncternal's strategy as it prepares for its first global Phase 3 study, ZILO-301, for zilovertamab, an experimental treatment for relapsed/refractory mantle cell lymphoma. DeSimone's insights are expected to enhance the company's patient-centric approach.
Oncternal Therapeutics (Nasdaq: ONCT) announced the grant of inducement awards to two new non-executive employees on January 3, 2023. Under the 2021 Employment Inducement Incentive Award Plan, the awards consist of options to purchase 79,500 shares of common stock, with a 10-year term and an exercise price aligned with the closing stock price on the grant date. These options vest over four years, incentivizing employee retention and aligning their interests with shareholders. The awards comply with Nasdaq rules, enhancing the company's recruitment strategy in the competitive biopharmaceutical sector.
Oncternal Therapeutics (ONCT) announced updated interim clinical data from the ongoing Phase 1/2 Study CIRM-0001 at the ASH 2022 Annual Meeting. The combination treatment of zilovertamab and ibrutinib achieved an objective response rate (ORR) of 89% in mantle cell lymphoma (MCL) patients, significantly outperforming historical monotherapy data. For chronic lymphocytic leukemia (CLL) patients with p53 mutations, landmark progression-free survival (PFS) reached 100% at 42 months. The combination was well-tolerated, with no serious adverse events attributed to zilovertamab.
Oncternal Therapeutics (Nasdaq: ONCT) announced the grant of an inducement award to Edward C. Dow, who joins as Vice President, Clinical Development. This award was made on November 14, 2022, under Oncternal's 2021 Employment Inducement Incentive Award Plan, entailing options for 125,000 shares. The options have a 10-year term and will vest over four years. Oncternal Therapeutics focuses on developing novel oncology therapies targeting hematological malignancies and prostate cancer, with ongoing clinical programs, including zilovertamab for relapsed/refractory mantle cell lymphoma.
Oncternal Therapeutics (Nasdaq: ONCT) has initiated the global Phase 3 study ZILO-301 targeting ROR1 in combination with ibrutinib for mantle cell lymphoma (MCL). The FDA granted IND clearance for ONCT-808, a CAR T therapy for aggressive B-cell lymphoma, with clinical data expected in 2023. The company reported a net loss of $11.1 million for Q3 2022, with total operating expenses of $11.7 million against grant revenue of $0.4 million. As of September 30, 2022, Oncternal has $70.6 million in cash, projected to fund operations into H1 2024.
Oncternal Therapeutics (Nasdaq: ONCT) announces the presentation of interim clinical data from its ongoing Phase 1/2 Study CIRM-0001 at the ASH Annual Meeting on December 10-13, 2022. This study evaluates zilovertamab, an investigational anti-ROR1 monoclonal antibody, combined with ibrutinib in patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and marginal zone lymphoma (MZL). The interim data has been accepted for oral presentation during a dedicated session, highlighting Oncternal's commitment to addressing critical unmet medical needs in oncology.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) will announce its third quarter 2022 financial results on November 3, 2022, after U.S. market close. A webcast at 2:00 p.m. PT will follow, providing a detailed business update and financial discussion. Oncternal focuses on innovative oncology therapies, particularly targeting cancers with unmet medical needs. The company's lead program, zilovertamab, is currently in multiple clinical trials for various hematological malignancies, while the ONCT-808 CAR T-cell therapy is moving into clinical stages for aggressive B cell lymphoma.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced the granting of an inducement award to Ariadne Jerue as the new Associate Director of Clinical Operations. This award, consisting of options to purchase 28,400 shares, follows Oncternal’s 2021 Employment Inducement Incentive Award Plan. The options will vest over four years, with an exercise price based on the stock’s closing price at the grant date. The award aims to attract new talent in the competitive biopharmaceutical sector.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) received FDA clearance for its Phase 1/2 IND application for ONCT-808, a CAR T therapy targeting ROR1 in patients with aggressive B cell non-Hodgkin's lymphoma. This marks a significant step for the company, focusing on patients who have previously failed CD19 CAR T treatment. The study is expected to begin soon, with interim results set to be presented at a scientific conference in 2023. Oncternal is also progressing in its study of zilovertamab, another therapy targeting ROR1, further expanding its oncology pipeline.
FAQ
What is the current stock price of Oncternal Therapeutics (ONCT)?
What is the market cap of Oncternal Therapeutics (ONCT)?
What does Oncternal Therapeutics specialize in?
What are the key products in Oncternal's pipeline?
What is zilovertamab?
What is ONCT-534?
How is Oncternal funded?
What makes ONCT-808 unique?
What is the significance of ONCT-216?
What are the current clinical trials for Oncternal's products?
Where can I find more information about Oncternal Therapeutics?
How does Oncternal aim to address unmet medical needs?
